TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25076

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.01 mg kg‐1
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.02 mg kg‐1
Number of subjects: 92

Group type: COMPARATOR
Intervention: Diazepam 0.125 mg kg‐1
Number of subjects: 92

Group type: COMPARATOR
Intervention: Diazepam 0.25 mg kg‐1
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Flunitrazepam double dose
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Flunitrazepam larger doses
Number of subjects: 92

Group type: COMPARATOR
Intervention: Diazepam larger doses
Number of subjects: 92
Study: 31882564

Group type: EXPERIMENTAL
Intervention: Placental DNA methylation markers
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Maternally imprinted gene DLGAP2
Number of subjects: 430
Study: 30294825

Group type: EXPERIMENTAL
Intervention: Nitrate-containing juice (n = 40)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Spironolactone (n = 44)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Doxazosin (n = 43)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo juice (n = 47)
Number of subjects: 105
Study: 27900446

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus bendamustine (G-B)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Bendamustine alone (B)
Number of subjects: 396
Study: 26176927

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 100
Study: 23271192

Group type: EXPERIMENTAL
Intervention: Aripiprazole 2 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aripiprazole (all doses)
Number of subjects: 15
Study: 20957705

Group type: EXPERIMENTAL
Intervention: Orlistat with cognitive‐behavioral therapy, guided‐self‐help (CBTgsh)
Number of subjects: 50
Study: 19609438

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) as regular therapy
Number of subjects: 159
Study: 16750253

Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 100

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 100
Study: 15133343

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (three times every 3 hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-treated healthy volunteers (control)
Number of subjects: 14
Study: 11358560

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate 0.25%
Number of subjects: 202

Group type: COMPARATOR
Intervention: Ointment base alone
Number of subjects: 202
Study: 9519354

Group type: EXPERIMENTAL
Intervention: buserelin plus cyproterone acetate
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: maximal androgen blockade (MAB)
Number of subjects: 695
Study: 8024677

Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mecamylamine (various doses)
Number of subjects: 27
Study: 2803886

Group type: EXPERIMENTAL
Intervention: Laryngoscopy and intubation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Blind nasal intubation
Number of subjects: 23
Study: 136815

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 28

Group type: COMPARATOR
Intervention: Acetylsalicylic-acid
Number of subjects: 28
Study: 30293693

Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard pharmacotherapy alone
Number of subjects: 43
Study: 27175903

Group type: EXPERIMENTAL
Intervention: CHANGE! intervention
Number of subjects: 60
Study: 26599219

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 25086490

Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty (RSA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hemiarthroplasty (HA)
Number of subjects: 62
Study: 22371898

Group type: EXPERIMENTAL
Intervention: Lersivirine (LRV) 2,400 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20188228

Group type: EXPERIMENTAL
Intervention: Land-based exercise program
Number of subjects: 204

Group type: COMPARATOR
Intervention: Non-exercise group (control)
Number of subjects: 204
Study: 17355729

Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy combined with anti-angiogenic agents (ranibizumab or pegaptanib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-angiogenic agents (ranibizumab or pegaptanib)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-angiogenic agents
Number of subjects: 0
Study: 16222916

Group type: EXPERIMENTAL
Intervention: Water fortified with 10 mg elemental iron and 100 mg ascorbic acid per liter
Number of subjects: 150

Group type: COMPARATOR
Intervention: Water containing only 100 mg ascorbic acid per liter
Number of subjects: 150
Study: 12208222

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1‐0.4 microg x kg(‐1) x min(‐1))
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 10521382

Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: LPS (4 ng/kg IV)
Number of subjects: 30
Study: 7484997

Group type: EXPERIMENTAL
Intervention: Mesalazine (1.5 g/day) for 12 weeks after surgery
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Presence of lesions at perioperative endoscopy (POE)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Absence of lesions at perioperative endoscopy (POE)
Number of subjects: 21
Study: 2049250

Group type: EXPERIMENTAL
Intervention: Low protein meal (10.5 g of protein)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High protein meal (30.5 g of protein)
Number of subjects: 8
Study: 7451775

Group type: EXPERIMENTAL
Intervention: Venom skin testing
Number of subjects: 128

Group type: COMPARATOR
Intervention: Whole body extract (WBE) skin testing
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Venom skin testing at concentrations of 1 microgram/ml or less
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 128
Study: 6299612

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both drugs (Propranolol and Atenolol)
Number of subjects: 6
Study: 31639058

Group type: EXPERIMENTAL
Intervention: Knowledge of mother on HIV exposed infant feeding practice
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Head of family being father
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Having family (relatives) support
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Information on HIV exposed infant feeding practice
Number of subjects: 358
Study: 29478874

Group type: EXPERIMENTAL
Intervention: Memory-Focused Cognitive Therapy (MFCT) sessions (5×120min in 1 week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (ongoing treatment-as-usual; TAU)
Number of subjects: 30
Study: 25873297

Group type: EXPERIMENTAL
Intervention: Empathy manipulation (recalled personal experiences of empathising with others) in Japan
Number of subjects: 160

Group type: COMPARATOR
Intervention: Neutral condition in Japan
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Empathy manipulation in Australia
Number of subjects: 160

Group type: COMPARATOR
Intervention: Neutral condition in Australia
Number of subjects: 160
Study: 24568566

Group type: EXPERIMENTAL
Intervention: Male who used a stimulant to study
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Nonmedical use of prescription stimulants (NMUPS) as a study aid
Number of subjects: 695
Study: 23075175

Group type: EXPERIMENTAL
Intervention: Peripheral-blood stem cells
Number of subjects: 551

Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 551
Study: 20454993

Group type: EXPERIMENTAL
Intervention: PACAP38
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: VIP
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17363405

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl PCA
Number of subjects: 28

Group type: COMPARATOR
Intervention: Thoracic epidural block with bupivacaine plus fentanyl
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 28
Study: 15874889

Group type: EXPERIMENTAL
Intervention: Prone position ventilation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Supine position ventilation
Number of subjects: 42
Study: 12592266

Group type: EXPERIMENTAL
Intervention: Betamethasone acetate + phosphate
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (after treatment)
Number of subjects: 105
Study: 10937985

Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 10226245

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 34
Study: 1755063

Group type: EXPERIMENTAL
Intervention: Chemotherapeutic intervention for Ascaris lumbricoides infection
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 1206
Study: 7041831

Group type: EXPERIMENTAL
Intervention: 150 mg levamisole
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 50 mg levamisole
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 150 mg levamisole (classical dosage schedule)
Number of subjects: 281
Study: 31496244

Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Number of subjects: 100
Study: 28321001

Group type: EXPERIMENTAL
Intervention: ARB/CCB combination therapy (irbesartan 100 mg + amlodipine 5 mg)
Number of subjects: 411

Group type: COMPARATOR
Intervention: ARB/diuretic combination (daily irbesartan 100 mg + trichlormethiazide 1 mg)
Number of subjects: 411
Study: 26445302

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) administered orally for 48 hours before and 24 hours after coronary angiography
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard hydration (isotonic saline)
Number of subjects: 132
Study: 23644107

Group type: EXPERIMENTAL
Intervention: Syndrome differentiation-based treatment with traditional Chinese medicine (TCM)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Oral losartan therapy (50 mg/day)
Number of subjects: 81
Study: 21538174

Group type: EXPERIMENTAL
Intervention: Slow, deep breathing (6 breaths per min)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Normal breathing (15 breaths per min)
Number of subjects: 267
Study: 19428297

Group type: EXPERIMENTAL
Intervention: Single oral dose of casopitant mesylate (150 mg)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: 3-day intravenous plus oral casopitant mesylate (90 mg intravenous on day 1 plus 50 mg oral on days 2 and 3)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 810
Study: 17021784

Group type: EXPERIMENTAL
Intervention: 5% trichloroacetic acid (TCA)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Ear drops containing antibiotic and corticosteroid (Control)
Number of subjects: 215
Study: 15506300

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu group (XF)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Jingzhi Xuefu Zhuyu group (JZ)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Yaodui group (YD)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 123
Study: 11511607

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10524688

Group type: EXPERIMENTAL
Intervention: Weekly MTX
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Every-other-week (EOW) MTX
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (EOW MTX)
Number of subjects: 51
Study: 7854226

Group type: EXPERIMENTAL
Intervention: General practitioners recognizing mental health problems at least once per week
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Barriers to referral
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Educational priorities
Number of subjects: 721
Study: 1937373

Group type: EXPERIMENTAL
Intervention: Pure alcohol (PA, 99.8%)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 50% glucose in water (G/W)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 3% NaCl solution
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal saline solution (N/S)
Number of subjects: 84
Study: 6129185

Group type: EXPERIMENTAL
Intervention: Insulin + cyclic SRIF (100 micrograms/hr i.v.) for ten hours
Number of subjects: 5

Group type: COMPARATOR
Intervention: Insulin alone (10 units as a bolus + infusion 1 U/hr)
Number of subjects: 5
Study: 31665303

Group type: EXPERIMENTAL
Intervention: I-RED strategy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study: 29790397

Group type: EXPERIMENTAL
Intervention: Unipolar hemiarthroplasty
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bipolar hemiarthroplasty
Number of subjects: 28
Study: 27091801

Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study: 24300751

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 22705428

Group type: EXPERIMENTAL
Intervention: Starvation
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cachexia
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: All three conditions (starvation, sarcopenia, cachexia)
Number of subjects: 187
Study: 20437554

Group type: EXPERIMENTAL
Intervention: GKI infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 18768029

Group type: EXPERIMENTAL
Intervention: Dental hygiene activities including prophylaxis, sealants application, topical fluoride, fluoride mouthrinses, and tooth brushing instructional activity.
Number of subjects: 888
Study: 15842138

Group type: EXPERIMENTAL
Intervention: Puerarin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional Western medical treatment (Control)
Number of subjects: 79
Study: 12578487

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg twice per day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 200
Study: 10475592

Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented milk formula
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard milk formula
Number of subjects: 2
Study: 8776276

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg 3 times daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 1377198

Group type: EXPERIMENTAL
Intervention: Teaching and reinforcement about babies' behavior from a child development specialist during NICU visits
Number of subjects: 41
Study: 6431461

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30151631

Group type: EXPERIMENTAL
Intervention: Improved expectations about length of sick leave during rehabilitation
Number of subjects: 168

Group type: COMPARATOR
Intervention: Reduced expectations about length of sick leave
Number of subjects: 168

Group type: COMPARATOR
Intervention: Consistently negative expectations about length of sick leave
Number of subjects: 168
Study: 29901548

Group type: EXPERIMENTAL
Intervention: Mother's milk feeding
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation among infants receiving mother's milk
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Introducing solids between 4 and 6 months CA
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall adherence to all recommendations
Number of subjects: 300
Study: 26976287

Group type: EXPERIMENTAL
Intervention: Combined incentive
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Individual incentive
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Team incentive
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control
Number of subjects: 304
Study: 21695523

Group type: EXPERIMENTAL
Intervention: Fat-rich diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Carbohydrate-rich diet
Number of subjects: 11
Study: 20216119

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 5
Study: 18400939

Group type: EXPERIMENTAL
Intervention: Raloxifene treatment
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 15797966

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/d, 16 wk)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (16 wk)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11885802

Group type: EXPERIMENTAL
Intervention: Frequency Doubling Technology (FDT) C20‐1 screening algorithm
Number of subjects: 574

Group type: COMPARATOR
Intervention: HFA 24-2 SITA-FAST
Number of subjects: 574
Study: 10326324

Group type: EXPERIMENTAL
Intervention: High dose cyclosporin A
Number of subjects: 208

Group type: COMPARATOR
Intervention: Low dose cyclosporin A
Number of subjects: 208
Study: 8567042

Group type: COMPARATOR
Intervention: Sodium-restricted diet (50 mmol/24 h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sodium-replete diet (200 mmol/24 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Remikiren (600 mg, single oral dose) during high sodium period
Number of subjects: 32
Study: 8392419

Group type: EXPERIMENTAL
Intervention: Continuous wave electron paramagnetic resonance (CW‐EPR) dosimetry using alanine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermoluminescent dosimetry (TLD)
Number of subjects: 0
Study: 3554643

Group type: EXPERIMENTAL
Intervention: Cyclosporine (15‐17 mg/kg/day)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cyclosporine (15‐17 mg/kg/day) + Prednisolone (0.3 mg/kg/day)
Number of subjects: 117
Study: 30863532

Group type: EXPERIMENTAL
Intervention: Newsletter plus handwritten Post-it®
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Newsletter plus printed Post-it®
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Newsletter only
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Handwritten Post-it® only
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Printed Post-it® only
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: No Post-it®
Number of subjects: 826

Group type: COMPARATOR
Intervention: No newsletter or Post-it®
Number of subjects: 826
Study: 27177100

Group type: EXPERIMENTAL
Intervention: Heart‐Gallbladder acupuncture treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture treatment
Number of subjects: 60
Study: 25707624

Group type: EXPERIMENTAL
Intervention: TAK-438 40 mg once daily for 7 days
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: TAK-438 (all dose levels)
Number of subjects: 108
Study: 22925832

Group type: EXPERIMENTAL
Intervention: 16 kilocalories per kilogram of body weight per week (KKW) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 KKW for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise (both doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antidepressant medications
Number of subjects: 0
Study: 22159777

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamins C/E supplementation (AS)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: AS + RT
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control - placebo
Number of subjects: 57
Study: 19346877

Group type: EXPERIMENTAL
Intervention: Home-based exercise and nutrition program
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 13
Study: 16979011

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 458
Study: 15568149

Group type: EXPERIMENTAL
Intervention: Real-time myocardial contrast echocardiography (MCE)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 99mTc-sestamibi single photon emission computed tomography (SPECT)
Number of subjects: 66
Study: 11401657

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 58
Study: 9474071

Group type: EXPERIMENTAL
Intervention: Emergency department visits (3 or more in the prior 6 months)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Difficulty performing work or activities due to physical health in the 4 weeks prior
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Discontinuing hospital-based treatment within 24 hours without achieving a peak expiratory flow rate of at least 50% of predicted
Number of subjects: 284
Study: 7527327

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 0